FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380482014> ?p ?o ?g. }

• W4380482014 abstract "The current treatment options for epidermal growth factor receptor (EGFR) mutation-positive lung cancer in the elderly with tyrosine kinase inhibitor (TKI) resistance are limited. Although chemotherapy combined with vascular endothelial growth factor inhibitors significantly improves progression-free survival (PFS) in TKI-resistant patients, it often cannot be tolerated in elderly patients, leading to treatment failure. Anlotinib is a small molecule inhibitor made in China. The application of low-dose anlotinib in elderly patients with TKI-resistant lung cancer deserves further investigation. A total of 48 elderly patients with non-small cell lung cancer (NSCLC) were enrolled to evaluate the efficacy of anlotinib combined with continuous EGFR-TKI vs. anlotinib monotherapy in patients with acquired EGFR-TKI resistance. Anlotinib was administered at a dose of 6-8 mg per day, lower than the normal dose and known as a low dose, which is well tolerated in elderly patients. There were 25 cases in the combination group and 23 cases in the anlotinib monotherapy group. The primary endpoint of the present study was PFS, and the secondary endpoints were overall survival (OS), response rate and toxicity. The median PFS (mPFS) was significantly longer in the combination group than that in the anlotinib monotherapy group: 6.0 months [95% confidence interval (CI), 4.35-7.65] compared with 4.0 months (95% CI, 3.38-4.62) (P=0.002). Analysis of the subgroups showed similar trends in results. The median OS was 32 months (95% CI, 22.04-41.96) in the combination group and 28 months (95% CI, 27.13-28.87) in the anlotinib monotherapy group (P=0.217). According to stratification analysis, second-line treatment with anlotinib combined with EGFR-TKI resulted in a better mPFS than third-line treatment (7.5 vs. 3.7 months, HR=3.477; 95% CI, 1.117-10.820; P=0.031). In the combination group, patients with gradual/local progression after EGFR-TKI failure had a longer mPFS than those with dramatic progression (7.5 vs. 6.0 months, HR=5.875; 95% CI, 1.414-10.460; P=0.015). Multivariate analyses showed that continuous EGFR-TKI combined with anlotinib after EGFR-TKI resistance was associated with longer PFS (P=0.019), whereas dramatic progression (P=0.014) had a detrimental effect on follow-up treatment. Grade 2 adverse events (AEs) were reported in four patients (17.39%) in the anlotinib monotherapy group and eight patients (32.00%) in the combination group. Of these, the most common grade 2 AEs were hypertension, fatigue, diarrhea, paronychia, mucositis and transaminase elevation. There were no grade 3/4/5 AEs. In conclusion, the present study demonstrated that low-dose anlotinib combined with EGFR-TKI is superior to anlotinib alone following EGFR-TKI failure, making it the preferred regimen for elderly patients with acquired EGFR-TKI resistance." @default.
• W4380482014 created "2023-06-14" @default.
• W4380482014 creator A5004678145 @default.
• W4380482014 creator A5034855502 @default.
• W4380482014 creator A5039951517 @default.
• W4380482014 creator A5061402622 @default.
• W4380482014 creator A5071813677 @default.
• W4380482014 creator A5077423550 @default.
• W4380482014 creator A5089556504 @default.
• W4380482014 creator A5092153722 @default.
• W4380482014 date "2023-06-13" @default.
• W4380482014 modified "2023-09-30" @default.
• W4380482014 title "Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients" @default.
• W4380482014 cites W1432092622 @default.
• W4380482014 cites W1990013637 @default.
• W4380482014 cites W1994539763 @default.
• W4380482014 cites W2019607817 @default.
• W4380482014 cites W2024502310 @default.
• W4380482014 cites W2040299716 @default.
• W4380482014 cites W2076668534 @default.
• W4380482014 cites W2111662961 @default.
• W4380482014 cites W2130162490 @default.
• W4380482014 cites W2132157071 @default.
• W4380482014 cites W2135192471 @default.
• W4380482014 cites W2139804581 @default.
• W4380482014 cites W2148036396 @default.
• W4380482014 cites W2148346100 @default.
• W4380482014 cites W2154969724 @default.
• W4380482014 cites W2160982674 @default.
• W4380482014 cites W2532106653 @default.
• W4380482014 cites W2560717039 @default.
• W4380482014 cites W2747382292 @default.
• W4380482014 cites W2757581310 @default.
• W4380482014 cites W2765831845 @default.
• W4380482014 cites W2770828094 @default.
• W4380482014 cites W2791667474 @default.
• W4380482014 cites W2793605704 @default.
• W4380482014 cites W2795708883 @default.
• W4380482014 cites W2797700531 @default.
• W4380482014 cites W2885503610 @default.
• W4380482014 cites W2886516627 @default.
• W4380482014 cites W2891059887 @default.
• W4380482014 cites W2892785659 @default.
• W4380482014 cites W2921434986 @default.
• W4380482014 cites W2955313665 @default.
• W4380482014 cites W2999417355 @default.
• W4380482014 cites W3009963727 @default.
• W4380482014 cites W3018570521 @default.
• W4380482014 cites W3028401904 @default.
• W4380482014 cites W3032247589 @default.
• W4380482014 cites W3110833960 @default.
• W4380482014 cites W3126928179 @default.
• W4380482014 cites W3135105663 @default.
• W4380482014 cites W3159404526 @default.
• W4380482014 cites W3191778845 @default.
• W4380482014 cites W3201632112 @default.
• W4380482014 cites W4205405376 @default.
• W4380482014 cites W4205501618 @default.
• W4380482014 cites W4229031486 @default.
• W4380482014 cites W4280558216 @default.
• W4380482014 cites W4280559098 @default.
• W4380482014 cites W4281984185 @default.
• W4380482014 doi "https://doi.org/10.3892/ol.2023.13909" @default.
• W4380482014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37415629" @default.
• W4380482014 hasPublicationYear "2023" @default.
• W4380482014 type Work @default.
• W4380482014 citedByCount "0" @default.
• W4380482014 crossrefType "journal-article" @default.
• W4380482014 hasAuthorship W4380482014A5004678145 @default.
• W4380482014 hasAuthorship W4380482014A5034855502 @default.
• W4380482014 hasAuthorship W4380482014A5039951517 @default.
• W4380482014 hasAuthorship W4380482014A5061402622 @default.
• W4380482014 hasAuthorship W4380482014A5071813677 @default.
• W4380482014 hasAuthorship W4380482014A5077423550 @default.
• W4380482014 hasAuthorship W4380482014A5089556504 @default.
• W4380482014 hasAuthorship W4380482014A5092153722 @default.
• W4380482014 hasBestOaLocation W43804820141 @default.
• W4380482014 hasConcept C121608353 @default.
• W4380482014 hasConcept C126322002 @default.
• W4380482014 hasConcept C143998085 @default.
• W4380482014 hasConcept C168563851 @default.
• W4380482014 hasConcept C203092338 @default.
• W4380482014 hasConcept C2776256026 @default.
• W4380482014 hasConcept C2776694085 @default.
• W4380482014 hasConcept C2778820342 @default.
• W4380482014 hasConcept C2779438470 @default.
• W4380482014 hasConcept C2780739268 @default.
• W4380482014 hasConcept C44249647 @default.
• W4380482014 hasConcept C71924100 @default.
• W4380482014 hasConcept C90924648 @default.
• W4380482014 hasConceptScore W4380482014C121608353 @default.
• W4380482014 hasConceptScore W4380482014C126322002 @default.
• W4380482014 hasConceptScore W4380482014C143998085 @default.
• W4380482014 hasConceptScore W4380482014C168563851 @default.
• W4380482014 hasConceptScore W4380482014C203092338 @default.
• W4380482014 hasConceptScore W4380482014C2776256026 @default.
• W4380482014 hasConceptScore W4380482014C2776694085 @default.
• W4380482014 hasConceptScore W4380482014C2778820342 @default.
• W4380482014 hasConceptScore W4380482014C2779438470 @default.
• W4380482014 hasConceptScore W4380482014C2780739268 @default.

• next